Reimbursement of Digital Therapeutics: Future Perspectives in Korea

Author:

Ju Jin Han1ORCID,Sim Boram1ORCID,Lee Jeongeun1ORCID,Lee Jin Yong123ORCID

Affiliation:

1. HIRA Research Institute, Health Insurance Review & Assessment Service, Wonju, Korea.

2. Public Healthcare Center, Seoul National University Hospital, Seoul, Korea.

3. Department of Health Policy and Management, Seoul National University College of Medicine, Seoul, Korea.

Publisher

The Korean Society of Cardiology

Subject

Cardiology and Cardiovascular Medicine,Internal Medicine

Reference48 articles.

1. Pear Therapeutics, Inc. Pear therapeutics press release [Internet]. Boston (MA). Pear Therapeutics. 2021. cited 2021 September 22. Available from: https://peartherapeutics.com/fda-obtains-fda-clearance-first-prescription-digital-therapeutic-treat-disease/

2. Adoption of Digital Technologies in Health Care During the COVID-19 Pandemic: Systematic Review of Early Scientific Literature

3. Digital health: a new dimension in rheumatology patient care

4. Apprehensions about Excessive Belief in Digital Therapeutics: Points of Concern Excluding Merits

5. Self-Reported Diet Management and Adherence to Dietary Guidelines in Korean Adults with Hypertension

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3